Metoclopramide Hcl Cf

Metoclopramide Hydrochloride, the active ingredient in Metoclopramide Hcl Cf, is a dopamine D2 receptor antagonist / prokinetic presented as an oral formulation for systemic use. It is used to treat nausea, vomiting and related gastrointestinal motility disorders in adults.

GNH USA supplies Metoclopramide Hcl Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Metoclopramide acts on the dopaminergic pathways and gastrointestinal motility to relieve several conditions: - Nausea and vomiting (including chemotherapy‑induced): reduces the frequency and severity of episodes. - Gastroparesis: accelerates gastric emptying and improves related symptoms. - Functional dyspepsia: alleviates upper abdominal discomfort and early satiety. - Post‑operative nausea and vomiting: prevents and treats nausea after surgical procedures.

Metoclopramide may cause a range of adverse reactions.

Common Side Effects: - Drowsiness - Fatigue - Restlessness - Diarrhea

Serious or Rare Side Effects: - Extrapyramidal reactions (e.g., acute dystonia) - Tardive dyskinesia with long‑term use - Neuroleptic malignant syndrome

Before initiating therapy, consider the following precautions: - Assess renal function: dose may need adjustment in severe renal impairment. - Monitor for extrapyramidal symptoms: especially during the first few days of treatment. - Limit duration of use: prolonged therapy increases risk of tardive dyskinesia. - Caution in patients with depression: may exacerbate depressive symptoms. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk (category unknown). - Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Metoclopramide can interact with several drug classes.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive risk of extrapyramidal symptoms. - CYP2D6 inhibitors (e.g., fluoxetine): increase metoclopramide plasma concentrations. - MAO inhibitors: may precipitate hypertensive crisis.

Moderate Interactions (Monitor Closely): - Anticholinergics: may diminish the pro‑kinetic effect. - Sedatives (e.g., benzodiazepines): enhanced drowsiness and CNS depression.